Cargando…

Metabolic Imaging in Prostate Cancer: Where We Are

In recent years, the development of diagnostic methods based on metabolic imaging has been aimed at improving diagnosis of prostate cancer (PCa) and perhaps at improving therapy. Molecular imaging methods can detect specific biological processes that are different when detected within cancer cells r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Testa, Claudia, Pultrone, Cristian, Manners, David Neil, Schiavina, Riccardo, Lodi, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101200/ https://www.ncbi.nlm.nih.gov/pubmed/27882307 http://dx.doi.org/10.3389/fonc.2016.00225

Ejemplares similares

Cancer treatment data available in European cancer registries: Where are we and where are we going?
por: Giusti, Francesco, et al.
Publicado: (2023)

Interpretation of 11C–choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer
por: Matti, A., et al.
Publicado: (2017)

Multiparametric magnetic resonance imaging for the differential diagnosis between granulomatous prostatitis and prostate cancer: a literature review to an intriguing diagnostic challenge
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
por: Zeng, Huihua, et al.
Publicado: (2021)

The Role of [(18)F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [(11)C]Choline PET/CT and Histopathological Analysis
por: Zanoni, Lucia, et al.
Publicado: (2021)

Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Where We Are and Where We Need to Go
por: Liu, Xiaohao, et al.
Publicado: (2020)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?
por: Mannavola, Francesco, et al.
Publicado: (2019)

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
por: Hu, Li-Feng, et al.
Publicado: (2021)

Where are we going with sentinel nodes mapping in ovarian cancer?
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2022)

Convolutional Neural Network Techniques for Brain Tumor Classification (from 2015 to 2022): Review, Challenges, and Future Perspectives
por: Xie, Yuting, et al.
Publicado: (2022)

Challenges in the Use of Artificial Intelligence for Prostate Cancer Diagnosis from Multiparametric Imaging Data
por: Corradini, Daniele, et al.
Publicado: (2021)

Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are
por: Saggioro, Mattia, et al.
Publicado: (2020)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
por: Giraudet, Anne-Laure, et al.
Publicado: (2021)

Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
por: Minciacchi, V R, et al.
Publicado: (2017)

Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
por: Dhawan, Annika, et al.
Publicado: (2022)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

The future of high-grade glioma: Where we are and where are we going
por: Rhun, Emilie Le, et al.
Publicado: (2015)

Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
por: Pan, Darren, et al.
Publicado: (2022)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Editorial: Current innovations in GI-oncology: Where do we stand?
por: Rumpold, Holger, et al.
Publicado: (2022)

The genetic patterns of bladder cancer. Where do we stand now?
por: Salagierski, Maciej
Publicado: (2013)

Bariatric and metabolic surgery in Asia: Where are we, and where are we going?
por: Yasuda, Kazuki
Publicado: (2018)

Editorial: Prostate Cancer: What We Know and What We Would Like to Know
por: Taverna, Gianluigi, et al.
Publicado: (2015)

Promoting Physical Activity in Pediatric Oncology. Where Do We Go from Here?
por: Viña, Carolina Chamorro, et al.
Publicado: (2013)

Methods of diffusion MRI tractography for localization of the anterior optic pathway: A systematic review of validated methods
por: Carrozzi, Alessandro, et al.
Publicado: (2023)

Editorial: Engineering Rumen Metabolic Pathways: Where We Are, and Where Are We Heading
por: Ungerfeld, Emilio M., et al.
Publicado: (2018)

Key issues in essential tremor genetics research: Where are we now and how can we move forward?
por: Testa, Claudia M.
Publicado: (2013)

Recurrent Glioblastoma: Where we stand
por: Roy, Sanjoy, et al.
Publicado: (2015)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
por: Markman, Maurie
Publicado: (2016)

The Metabolic Phenotype of Prostate Cancer
por: Eidelman, Eric, et al.
Publicado: (2017)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
por: Friedlaender, Alex, et al.
Publicado: (2019)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Chemotherapy for hormone-resistant prostate cancer: Where are we today?
por: Buchler, Tomas, et al.
Publicado: (2007)

Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?
por: Małkiewicz, Bartosz, et al.
Publicado: (2022)

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

Osteoarthritis and Diabetes: Where Are We and Where Should We Go?
por: Alenazi, Aqeel M., et al.
Publicado: (2023)

Editorial: Preoperative Frailty Risk Assessment Prior to Esophagectomy, Where Are We?
por: Fay, K. A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_asl663qs2qqk3jjsusqj7rigmc